Treatment analysis of intravenous thrombolysis in patients with mild ischemic stroke

doi:10.3969/j.issn.1672-6731.2019.12.012

Abstract

Abstract:

Objective To analysis the safety and outcome of intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA) in patients with acute mild ischemic stroke. Methods From November 2017 to October 2018, 252 patients with acute mild ischemic stroke who were admitted into our hospital within 4.50 h after onset (84 patients in intravenous thrombolysis group, 108 patients in aspirin and clopidogrel group, and 60 patients in aspirin or clopidogrel group). The general condition, the level of high-sensitivity C-reactive protein (hs-CRP) and erythrocyte sedimentation (ESR) were compared among 3 groups. The modified Rankin Scale (mRS) were evaluated on 7 d after admission or at earlier discharge, and 21 and 90 d. Symptomatic intracranial hemorrhage rates were compared among 3 groups. Results There were no significant difference in general clinical data, the initial level of hs-CRP and ESR between the intravenous thrombolytic group and the 2 non-thrombolysis groups. At 7 d after admission or earlier discharge, the descending range of hs-CRP and ESR in 3 groups were significant (P=0.000, for all); there were significant differences among the 3 groups (P=0.000, for all); pairwise comparison of 3 groups showed that the levels of hs-CRP and ESR in intravenous thrombolytic group at 7 d were significantly lower than aspirin and/or clopidogrel group (P=0.000, 0.000; P=0.000, 0.010). There was no significant difference in the rate of intracranial hemorrhage between thrombolytic group and other 2 groups at 24 h after treatment[1.19% (1/84) vs. 0 (0/168); χ²=2.008, P=0.366]. At 7 d after admission or earlier discharge, the intravenous thrombolytic group had better prognosis than aspirin and/or dopidogrel group (P=0.043, 0.012); At 21 and 90 d, the intravenous thrombolytic group had better prognosis than aspirin or clopidogrel group (P=0.021, 0.037); but compared with aspirin and clopidogrel group, there was no significant difference (P=0.070, 0.053). Conclusions Patients with mild ischemic stroke, especially that may induce disability should be treated with rt-PA intravenous thrombolysis timely. If it impossible by any causes, aspirin and clopidogrel should be given within 24 h after onset.

Key words: Stroke, Brain ischemia, Tissue plasminogen activator

摘要：

目的探讨重组组织型纤溶酶原激活物（rt-PA）治疗急性轻型缺血性卒中的有效性和安全性。方法纳入2017年11月至2018年10月发病4.50 h内入院的252例急性轻型缺血性卒中患者，分别行rt-PA静脉溶栓（静脉溶栓组，84例）、阿司匹林联合氯吡格雷双联抗血小板（双抗组，108例），以及阿司匹林或氯吡格雷抗血小板（单抗组，60例）治疗，治疗后24 h采用CT或MRI观察有无颅内出血，比较治疗前后血清超敏C-反应蛋白（hs-CRP）和红细胞沉降率（ESR）表达变化，并于入院后7 d、发病后21和90 d行改良Rankin量表评分判断预后。结果入院后7 d，不同治疗组患者血清hs-CRP（均P=0.000）和ESR（均P=0.000）水平降低，其中双抗组和单抗组血清hs-CRP（P=0.000，0.000）和ESR（P=0.000，0.010）高于静脉溶栓组；治疗后24 h，静脉溶栓组与抗血小板组颅内出血发生率差异无统计学意义[1.19%（1/84）对0（0/168）；χ²=2.008，P=0.366]。入院后7 d，静脉溶栓组预后良好率高于双抗组（P=0.043）和单抗组（P=0.012）；发病后21和90 d，静脉溶栓组预后良好率仅高于单抗组（P=0.021，0.037）。结论对于轻型缺血性卒中患者，尤其是症状轻微但可致残的患者应及时行rt-PA静脉溶栓，而因各种原因未能接受静脉溶栓治疗的患者则需在发病24小时内及时行阿司匹林联合氯吡格雷双联抗血小板治疗。

关键词: 卒中, 脑缺血, 组织型纤溶酶原激活物

SONG Zhao-hui, TONG Yan-na, DUAN Hong-lian, FENG Jing, MENG Fan-hua, DU Hui-shan, WANG Jia-wei. Treatment analysis of intravenous thrombolysis in patients with mild ischemic stroke[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2019, 19(12): 975-980.

宋兆慧, 童燕娜, 段洪连, 封靖, 孟繁花, 杜会山, 王佳伟. 轻型缺血性卒中患者静脉溶栓治疗分析[J]. 中国现代神经疾病杂志, 2019, 19(12): 975-980.

/ / Recommend / Download Citations

URL: https://journal11.magtechjournal.com/cjcnn/EN/10.3969/j.issn.1672-6731.2019.12.012

https://journal11.magtechjournal.com/cjcnn/EN/Y2019/V19/I12/975

References

[1] European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008[J]. Cerebrovasc Dis, 2008, 25:457-507.
[2] Strbian D, Piironen K, Meretoja A, Sairanen T, Putaala J, Tiainen M, Artto V, Rantanen K, Häppölä O, Kaste M, Lindsberg PJ; Helsinki Stroke Thrombolysis Registry Group.Intravenous thrombolysis for acute ischemic stroke patients presenting with mild symptoms[J]. Int J Stroke, 2013, 8:293-299.
[3] Nedeltchev K, Schwegler B, Haefeli T, Brekenfeld C, Gralla J, Fisher U, Arnold M, Remonda L, Schroth G, Mattle HP.Outcome of stroke with mild or rapidly improving symptoms[J].Stroke, 2007, 38:2531-2535.
[4] Zhao B, Wang JW. Progress of immune mechanism and immune-modulating therapy after ischemic stroke[J]. Zhongguo Zu Zhong Za Zhi, 2017, 12:425-431.[赵博, 王佳伟. 缺血性卒中后免疫机制及免疫调节治疗进展[J]. 中国卒中杂志, 2017, 12:425-431.]
[5] Chinese Society of Neurology, Chinese Stroke Society. Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018[J]. Zhonghua Shen Jing Ke Za Zhi, 2018, 51:666-682.[中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志, 2018, 51:666-682.]
[6] Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, Wang C, Li H, Meng X, Cui L, Jia J, Dong Q, Xu A, Zeng J, Li Y, Wang Z, Xia H, Johnston SC; CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack[J]. N Engl J Med, 2013, 369:11-19.
[7] National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group. Recombinant tissue plasminogen activator for minor strokes:the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience[J]. Ann Emerg Med, 2005, 46:243-252.
[8] Willey JZ, Khatri P, Khoury JC, Merino JG, Ford AL, Rost NS, Gonzales NR, Ali LK, Meyer BC, Broderick JP. Variability in the use of intravenous thrombolysis for mild stroke:experience across the SPOTRIAS network[J]. J Stroke Cerebrovasc Dis, 2013, 22:318-322.
[9] Wang YL, Zhao XQ, Liu XF, Zeng JS, Xu YM, Zhao G, Xu AD, Fan DS, Chen KN, He L, Peng B, Dong Q, Huang JX, Liu YJ, Shuai J, Luo BY, Wang X, Miao ZR. Guidelines for diagnosis and treatment of high risk non-disabling ischemic cerebrovascular events[J]. Zhongguo Zu Zhong Za Zhi, 2016, 11:481-491.[王伊龙, 赵性泉, 刘新峰, 曾进胜, 许予明, 赵钢, 徐安定, 樊东升, 陈康宁, 何俐, 彭斌, 董强, 黄家星, 刘亚杰, 帅杰, 罗本燕, 汪昕, 缪中荣. 高危非致残性缺血性脑血管事件诊疗指南[J]. 中国卒中杂志, 2016, 11:481-491.]
[10] Chen W, Pan Y, Zhao X, Liu L, Li H, Liao X, Wang C, Wang Y, Wang Y. Intravenous thrombolysis in Chinese patients with different subtype of mild stroke:thrombolysis in patients with mild stroke[J]. Sci Rep, 2017, 7:2299.
[11] Hassan AE, Hassanzadeh B, Tohidi V, Kirmani JF. Very mild stroke patients benefit from intravenous tissue plasminogen activator without increase of intracranial hemorrhage[J]. South Med J, 2010, 103:398-402.
[12] Ahmed N, Wahlgren N, Grond M, Hennerici M, Lees KR, Mikulik R, Parsons M, Roine RO, Toni D, Ringleb P; SITS Investigators. Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke:an updated analysis from SITS-ISTR[J]. Lancet Neurol, 2010, 9:866-874.
[13] Huisa BN, Raman R, Neil W, Ernstrom K, Hemmen TM.Intravenous tissue plasminogen activator for patients with minor ischemic stroke[J]. J Stroke Cerebrovasc Dis, 2012, 21:732-736.
[14] You S, Saxena A, Wang X, Tan W, Han Q, Cao Y, Liu CF.Efficacy and safety of intravenous recombinant tissue plasminogen activator in mild ischaemic stroke:a Meta-analysis[J]. Stroke Vasc Neurol, 2018, 3:22-27.
[15] Khatri P, Kleindorfer DO, Devlin T, Sawyer RN Jr, Starr M, Mejilla J, Broderick J, Chatterjee A, Jauch EC, Levine SR, Romano JG, Saver JL, Vagal A, Purdon B, Devenport J, Pavlov A, Yeatts SD; PRISMS Investigators. Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits:the PRISMS randomized clinical trial[J]. JAMA, 2018, 320:156-166.
[16] Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY; Clinical Research Collaboration; Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA[J]. N Engl J Med, 2018, 379:215-225.
[17] Smith EE, Fonarow GC, Reeves MJ, Cox M, Olson DM, Hernandez AF, Schwamm LH. Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator:findings from get with the guidelines-stroke[J]. Stroke, 2011, 42:3110-3115.
[18] Khatri P, Conaway MR, Johnston KC; Acute Stroke Accurate Prediction Study (ASAP) Investigators. Ninety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic stroke[J]. Stroke, 2012, 43:560-562.
[19] Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, Shinohara Y; Japan Alteplase Clinical Trial (J-ACT) Group. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset:Japan Alteplase Clinical Trial (J-ACT)[J]. Stroke, 2006, 37:1810-1815.

Please choose a citation manager

Content to export